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Abstract: 
 
Human mast cells and basophils that express the high-affinity immunoglobulin E (IgE) receptor, 
Fcɛ receptor 1 (FcɛRI), have key roles in allergic diseases. FcɛRI cross-linking stimulates the 
release of allergic mediators1. Mast cells and basophils co-express FcγRIIb, a low affinity 
receptor containing an immunoreceptor tyrosine-based inhibitory motif and whose co-
aggregation with FcɛRI can block FcɛRI-mediated reactivity2,3,4. Here we designed, expressed 
and tested the human basophil and mast-cell inhibitory function of a novel chimeric fusion 
protein, whose structure is γHinge-CHγ2-CHγ3-15aa linker-CHɛ2-CHɛ3-CHɛ4. This Fcγ–Fcɛ 
fusion protein was expressed as the predicted 140-κD dimer that reacted with anti-human ɛ- and 
γ-chain specific antibodies. Fcγ–Fcɛ bound to both human FcɛRI and FcγRII. It also showed 
dose- and time-dependent inhibition of antigen-driven IgE-mediated histamine release from fresh 
human basophils sensitized with IgE directed against NIP (4-hydroxy-3-iodo-5-
nitrophenylacetyl). This was associated with altered Syk signaling. The fusion protein also 
showed increased inhibition of human anti-NP (4-hydroxy-3-nitrophenylacetyl) and anti-dansyl 
IgE-mediated passive cutaneous anaphylaxis in transgenic mice expressing human FcɛRIα. Our 
results show that this chimeric protein is able to form complexes with both FcɛRI and FcγRII, 
and inhibit mast-cell and basophil function. This approach, using a Fcγ–Fcɛ fusion protein to co-
aggregate FcɛRI with a receptor containing an immunoreceptor tyrosine-based inhibition motif, 
has therapeutic potential in IgE- and FcɛRI-mediated diseases. 
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Article: 
 
Allergen aggregation of IgE bound to FcɛRI induces release of preformed mediators and 
synthesis of later acting leukotrienes and chemokines from mast cells and basophils5. This 
process has a major role in many of human diseases such as asthma, allergic rhinitis, chronic 
urticaria, angioedema and anaphylaxis. FcɛRI aggregation induces release of preformed 
mediators and synthesis of later-acting leukotrienes, chemokines and cytokines5. The FcɛRI is a 
heterotetramer consisting of a single IgE-binding α-subunit, a β-subunit and two disulfide-linked 
γ-subunits. The β- and γ-subunit cytoplasmic tails each contain a conserved immunoreceptor 
tyrosine-based activation motif (ITAM). Cross-linking FcɛRI via IgE bound to multivalent 
antigen activates tyrosine phosphorylation of ITAMs, thereby initiating downstream signaling6. 
Mast cells and basophils co-express FcγRIIb, which contains two extracellular immunoglobulin-
like loops and a single conserved immunoreceptor tyrosine-based inhibition motif (ITIM) within 
its cytoplasmic tail7. FcγRIIb may co-aggregate with FcɛRI under physiologic conditions. It is 
hypothesized that when FcγRIIb aggregates, it induces inhibitory signaling via SH2-domain-
containing inositol 5-phosphatase (SHIP) and phosphorylation of FcγRIIb requires the co-
aggregation with FcɛRI (refs. 8,9). Aggregating FcγRII to FcɛRI leads to the rapid tyrosine 
phosphorylation of the FcγRIIb ITIM tyrosine by FcɛRI-associated Lyn and inhibition of FcɛRI 
signaling10,11,12,13. To take advantage of this FcγRIIb-negative signaling in human basophils and 
mast cells, we constructed a single chimeric human bifunctional protein (GE2) engineered by 
fusing the human Fcγ1 and Fcɛ. Here we show that this chimeric protein is able to inhibit IgE-
mediated in vitro activation of human basophils and mast cells and in vivo activation of human 
FcɛRIα-bearing mast cells in FcɛRIa transgenic mice. This approach using chimeric Fcγ proteins 
provides a platform for non-specific as well as future antigen-specific inhibition of IgE–FcɛRI-
mediated reactivity in a host of human diseases. 
 
Human genomic DNA encoding the IgG γ1 constant region extends from the hinge through the 
CH3 domain. This sequence was initially cloned into a mammalian expression vector with a 
cytomegalovirus promoter and a murine immunoglobulin κ-chain leader sequence. Genomic 
DNA of the human e heavy chain CH2 through CH4 domains was placed after the CHγ3. 
Between Fcγ1 and Fcɛ, we placed a 15 amino-acid linker (Gly4Ser)3, which has been used in 
single-chain Fv fragment expression14. This flexible peptide linker facilitates chain pairing and 
minimizes refolding and aggregation problems encountered when the two chains are expressed 
individually. The fusion protein contained the binding sites for FcɛRI (CHɛ2–CHɛ3) and for 
FcγRII (CHγ2–CHγ3)15,16. The first constant region domains (CHγ1 or CHɛ1) were deleted as 
this domain associates with BiP (immunoglobulin heavy-chain binding protein) and a fusion 
protein containing these regions was not expressed17. SDS–PAGE demonstrated the Fcγ1–Fcɛ 
fusion protein was expressed as the predicted ∼140-kD dimer. Western-blot analysis and ELISA 
testing demonstrated that the GE2 protein was recognized by antibodies specific for human ɛ and 
γ chains. 
 
Binding of GE2 to both the human FcɛRI and FcγRII was demonstrated using CHO3D10, a 
human FcɛRIα-transfected cell line and HMC-1, which expresses human FcγRII but not FcɛR 
(ref. 18). GE2 protein bound to both FcɛRI and FcγRII in a fashion equivalent to human IgE and 
IgG, respectively, as assessed by flow cytometry (data not shown). These results demonstrate 
that expressed GE2 protein is properly folded so as to preserve bifunctional heterotypic FcR 
binding. 
 
Fresh human basophils expressing both FcɛRI and FcγRII can be passively sensitized with 
chimeric human IgE specific for NIP (4-hydroxy-3-iodo-5-nitrophenylacetyl) and then histamine 
release induced by cross-linking the anti-NIP IgE–FcɛRI complex with NIP-BSA (ref. 19). We 
sensitized basophils with 1 μg/ml human anti-NIP IgE, plus doses of GE2 ranging from 0.01 to 
10 μg/ml for 1 hour before activation with 50 ng/ml NIP-BSA (Fig. 1a). Myeloma IgE (PS 
myeloma) was used as a control. We found that 1 μg GE2 at 1 μg per ml inhibited almost half of 
histamine release, whereas at 10 μg/ml GE2 gave an average of 84% inhibition. 10 μg of non-
specific PS IgE only decreased histamine release by 19%. Adding the GE2 at the same time as 
the IgE anti-NIP gave optimal inhibition. The longer the delay in GE2 addition following 
sensitization with IgE anti-NIP, the less the inhibition (Fig. 1b). These results show that the 
inhibition of antigen-driven histamine release induced by GE2 is dependent on time and dosage. 
We obtained similar results with cultured human mast cells; a dose of 1 μg caused 50% 
inhibition of IgE-mediated degranulation (data not shown). Cross-linking of GE2 by adding an 
anti-IgG antibody in vitro along with GE2 caused enhanced inhibition of IgE-mediated release 
(data not shown). In performing this experiment, we sought to mimic what may occur in 
vivo should subjects given GE2 make an antibody response against it. The actual fate of antibody 
bound GE2, should it occur in vivo, is not possible to predict. 
 
 
Figure 1: Dose- and time- dependent inhibition of basophil histamine release using GE2. a, Dose-dependence. 
Results are representative of 3 separate donors, each done in duplicate. b, Time-dependence. Results are 
representative of 2 separate donors, each done in duplicate. For both panels: *, significant differences in histamine 
release (P 〉 0.05), comparing the two indicated conditions. Total histamine in the donor basophils was 1.2 μg per 1 
× 106 basophils. 
 
Tyrosine phosphorylation of Syk is a critical step in human mast cell and basophil mediator 
release19. Cross-linking FcɛRI on human basophils with IgE directed to NIP and NIP-BSA 
induces substantial tyrosine phosphorylation of Syk which was markedly reduced in cells pre-
incubated with GE2 (Fig. 2). Thus, GE2 co-aggregation of FcɛRI and FcγRII inhibits IgE-
mediated Syk phosphorylation, which may contribute to the inhibition of histamine release. 
 
 
Figure 2: Co-aggregation of FcγRII and FcɛR1 by GE2 inhibits FcɛRI-mediated Syk phosphorylation. 
Immunoprecipitates were analyzed by western blotting with antibody against phosphotyrosine (top row), followed 
by anti-Syk antibody (bottom row). The top row represents phosphorylated Syk and the bottom row represents total 
Syk. Each lane shows Syk immunoprecipitated from 5 × 106 basophils. Results represent 2 separate experiments. 
 
Transgenic mice altered to express the human FcɛRIα and with the murine FcɛRIα chain 
knocked out demonstrate allergic reactivity mediated by passively administered human IgE 
antibody along with antigen20,21. The human FcɛRIα chain is coupled with the mouse β and γ 
chains to form a functional chimeric human/mouse FcɛRI. This model takes advantage of the fact 
that murine mast cells also express FcγRIIb that can interact well with human IgG. This is in 
contrast to the lack of interaction between the murine FcɛRI and human IgE. We used passive 
cutaneous anaphylaxis (PCA) to test the GE2 protein's ability to block IgE-driven FcɛRI-
mediated mast-cell release. We intradermally primed transgenic mice with 250 ng of chimeric 
human anti-NP (4-hydroxy-3-nitrophenylacetyl) IgE and simultaneously injected individual sites 
with saline, GE2 or IgE myeloma protein. Four hours later, mice were given a systemic 
challenge with 0.5 mg NP-BSA plus 1% Evans Blue intravenously. The intensity of the PCA at 
each site was assessed by the size of the skin bluing after 30 min. The size and color intensity of 
the reaction at the sites of GE2 injection were decreased compared with sites injected with an 
equivalent amount of human IgE myeloma (Fig. 3). Similar results were obtained using 
genetically engineered human IgE anti-dansyl antibody and dansyl-BSA as an antigen. A total of 
30 mice were tested and the GE2 was 2–4 times more potent than purified control human IgE in 
its ability to block PCA. 
 
Our results demonstrate that a single chimeric molecular human protein consisting of Fcγ1 plus 
Fcɛ directly inhibits in vitro histamine release from human basophils and also inhibits humanized 
FcɛRI-mediated mast-cell degranulation in transgenic mice. GE2 was more potent than control 
human IgE in all assays. Even if the GE2 protein did not have a 15 amino-acid linker between 
the two segments of 'normal' human Fcγ1 and Fcɛ, it would likely be recognized as foreign and 
induce an antibody response. With the 15 amino-acid linker, it is highly likely that antibody 
against GE2 would be expressed and will be primarily directed at this linker region. In fact, such 
an antibody response to GE2 may well prove advantageous as antibodies against GE2 will lead 
to increased cross-linking of Fcγ and Fcɛ receptors and should enhance inhibition of basophil 
and mast-cell function as we have observed in vitro using an anti-IgG antibody. This truncated 
Fcγ–Fcɛ fusion protein, GE2, provides a novel approach for the immunotherapy of diseases 
mediated via the FcɛR such as allergic asthma, allergic rhinitis, chronic urticaria, angioedema 
and anaphylaxis. Replacement of the Fcɛ sequence in our construct with specific allergen genes 
will result in chimeric bifunctional proteins. We predict that these proteins will have the ability 
to inhibit mast-cell and basophil reactivity in an antigen-specific manner rather than in the global 
fashion of GE2. Such novel antigen-specific reagents may be useful in allergen immunotherapy. 
 
 
Figure 3: In vivo immunoglobulin Fcγ-Fcɛ fusion protein inhibits IgE-mediated degranulation in transgenic mice. 
a–d, Mice were injected intradermally with the following: a, anti-NP IgE; b, saline; c, anti-NP IgE and GE2; d, anti-
NP IgE and IgE myeloma. 
 
Methods 
 
Construction and expression. To construct the human Fcγ–Fcɛ chimeric gene, the human IgE 
Fc region (CH2-CH3-CH4) was amplified from pAG vector (provided by S.L. Morrison), 
containing the whole e genomic DNA. The 5′ end primer was 5′-
GCTCGAGGGTGGAGGCGGTTCAGGCGGAGGTGG CTCTGGCGGTGGCGGATCGTTCA
CCCCGCCCACCGTGAAG-3′, containing a flexible linker sequence and a XhoI site. The 3′ end 
primer was 5′-GGCGGCCGCTCATTTACCGGGATTTACAGACAC-3′, containing a NotI site. 
After amplification, PCR products were cloned into pCR2.1 vector (Invitrogen, Carlsbad, 
California) and sequenced. Then the XhoI-NotI fragment was inserted into SalI-NotI site of pAN 
expression vector (from S.L. Morrison), containing the human genomic IgG γ1 constant region 
from hinge through the end of CH3. The IgE Fc region was placed downstream of the IgG 
γ1 constant region in frame with the CH3 and joined by a (Gly4Ser)3 flexible linker. The 
expression vector containing the immunoglobulin Fcγ–Fcɛ chimeric gene was transfected into 
SP2/0 cells. The Fcγ–Fcɛ fusion protein GE2 was expressed in cell-culture supernatants and 
purified by using an anti-human IgE affinity column. 
 
Western-blot analysis. The purified GE2 protein was run on 7.5% SDS–PAGE and then 
transferred into Immobilon transfer membranes (Millipore, Bedford, Massachusetts). For protein 
detection, blots were probed with either goat anti-human IgE (ɛ chain-specific) or goat anti-
human IgG (γ chain-specific) conjugated to alkaline phosphatase (KPL, Gaithersburg, 
Maryland). Color development was performed with an alkaline phosphatase conjugated substrate 
kit (BIO-RAD, Hercules, California). 
 
Binding analysis. Human FcR binding of the purified GE2 protein was tested by binding to 
FcɛRI-transfected CHO3D10 cells and HMC-1 cells expressing FcγRII and then analyzed by 
flow cytometry (FACSCalibur) using the FITC-conjugated anti-human IgE and anti-human IgG1 
reagents (Biosource, Camarillo, California). 
 
Histamine release. Acid-stripped Percoll-enriched human blood basophils were sensitized with 
chimeric human anti-NIP IgE (10 μg/ml) at 37 °C in a 5% CO2incubator and 1 h later, 
challenged with 50 ng of NIP-BSA (ref. 19). Histamine release was measured in the supernatants 
30 min later. GE2 or control human myeloma IgE was added at various doses and times to test 
the effects on histamine release. 
 
Measurement of Syk phosphorylation. NIP-sensitized basophils were incubated with or 
without GE2 (10 μg/ml), washed and challenged for 2, 5 or 15 min with 50 ng/ml NIP-BSA. 
Treated or control NIP-IgE sensitized basophils were lysed in 400 μl of 50 mM Tris (pH 7.5), 
150 mM NaCl, 1% Brij, 1 mM sodium orthovanadate and 1 μg/ml each of antipain, leupeptin, 
aprotinin and phenylmethanesulfonyl fluoride (PMSF) and incubated for 10 min on ice. Immune 
complexes were generated by incubating clarified supernatants with anti-Syk pre-adsorbed to 
protein A-Sepharose beads (Pharmacia, Uppsala, Sweden). Proteins were separated by SDS–
PAGE, transferred to nitrocellulose and phosphoproteins identified by anti-phosphotyrosine 
immunoblotting using enhanced chemiluminescence detection reagents (ECL, Amersham, 
Piscataway, New York). After probing with anti-phosphotyrosine antibody, blots were stripped 
for 30 min with 100 mM 2-mercaptoethanol, 2% SDS (w:v), and 0.5 M Tris-HCl buffer (pH 6.8) 
at 50 °C, and then reprobed with anti-Syk antibody (1 μ/ml). 
 
Passive cutaneous anaphylaxis. Transgenic mice expressing the human FcɛRIα chain and with 
the murine FcɛRIα chain knocked out20 were primed intradermally with 250 ng of NP-specific 
recombinant human IgE (ref. 21) in 50 μl saline. Individual sites were injected with saline, GE2 
or IgE myeloma protein simultaneously. 4 h later mice were then given an intravenous challenge 
with 1.5 mg/ml of NP-BSA plus 1% Evans blue in 300 μl saline solution. Cutaneous anaphylaxis 
was assessed visually by the blue dye leakage from blood vessels into the skin. 
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